Cancer Care Specialists | Oncology and Hematology Department

Research site

Location

5423 Reno Corporate Drive, Reno, Nevada, United States of America

Website

https://www.ccsreno.com/

Site insights

Top conditions

Top treatments

Alisertib

Zongertinib

Doxorubicin Hydrochloride

Divarasib

Pembrolizumab

PF-07220060

Blinatumomab

CPI-0610

Paclitaxel

Elotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Mari Toumaian

Verified by this site

Active trials

14 of 23 total trials

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting

Essential Thrombocythemia

Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carbop...

Enrolling

KRAS G12C Lung Cancer

Non-Small Cell Lung Cancer

Drug: Cisplatin

Drug: Pemetrexed

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with be...

Active, not recruiting

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: Alcestobart

Drug: Bevacizumab or Bevacizumab biosimilar

Locations recently updated

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) (ALISCA-Lung2)

The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with pa...

Enrolling

Small Cell Lung Cancer ( SCLC )

Drug: Alisertib

Drug: Paclitaxel

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in parti...

Enrolling

Hormone Receptor Positive HER-2 Negative Breast Cancer

Metastatic Breast Cancer

Drug: Alisertib

Drug: Endocrine therapy

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Active, not recruiting

Multiple Myeloma

Drug: Selinexor

Drug: Elotuzumab

A Study of Rusfertide in Adults With Polycythemia Vera (PV) (VERIFY)

Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (KRASCENDO 3)

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolu...

Enrolling

Non-small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Divarasib

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Active, not recruiting

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumour...

Active, not recruiting

Lung Cancer, Non-squamous, Non-small Cell

Drug: carboplatin

Drug: zongertinib

Locations recently updated

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment i...

Enrolling

Non-small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Atezolizumab

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting

Myelofibrosis

Post-essential Thrombocythemia Myelofibrosis

Drug: Placebo

Drug: Pelabresib

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib...

Active, not recruiting

Early Breast Cancer

Drug: Goserelin

Drug: Ansastrozole

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vin...

Active, not recruiting

Large B-cell Lymphoma

Drug: Golcadomide

Drug: Doxorubicin